KRAS Oncoprotein Signaling in Cancer | NEJM
Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients.
Related Articles
Opinion | How Doctors and Nurses Can Protect Undocumented Immigrants
Doctors have a responsibility to reassure their patients, regardless of immigration status, that they are welcome and protected.
The Future of Gender-Affirming Care — A Law and Policy Perspective on the Cass Review | NEJM
The Cass Review on gender-affirming care, which has been used to justify bans in U.S. states, transgresses medical law, policy, and practice, which puts it…
Early TAVR for Asymptomatic Severe Aortic Stenosis | NEJM
Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. Research findings …
A 41-Year-Old Man with Syncope, Ankle Swelling, and Abnormal Chest Imaging | NEJM
Case Records of the Massachusetts General Hospital from The New England Journal of Medicine — A 41-Year-Old Man with Syncope, Ankle Swelling, and Abnormal Chest…
Manu Malbrain on LinkedIn: Fluid Accumulation Syndrome
💧 Understanding Fluid Accumulation Syndrome in Sepsis and Septic Shock 💧 🚨 In critically ill patients with sepsis or septic shock, managing fluid balance…
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer | NEJM
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of…
Exogenous Lipoid Pneumonia | NEJM
A 38-year-old woman with a history of disordered eating was found to have ground-glass opacities on a chest CT. Cytologic examination of bronchoalveolar-lavage fluid showed…
Schrödinger’s Cancer | NEJM
No longer able to ignore the nagging ache between his shoulder blades, a physician begins a diagnostic journey that may — or may not —…
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM
Original Article from The New England Journal of Medicine — Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Paper of the Day
Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2023
